Metformin may lower cancer risk in people with Type 2 diabetes

A commonly prescribed diabetes drug, metformin, reduces the overall cancer risk in people with Type 2 diabetes, a large systematic review study finds. The results to be presented at The Endocrine Society's 94th Annual Meeting in Houston.

" increases the risk for several types of cancer," said lead author Diego Espinoza-Peralta, MD, an endocrinologist with Mexico's National Institute of Medical Sciences and Nutrition (Instituto Nacional de Ciencias Medicas y Nutricion) in Mexico City. "Our findings suggest that the regular use of metformin—a low-cost medication— reduces this risk, compared with not taking metformin."

Espinoza-Peralta and his colleagues conducted a systematic review and meta-analysis, or combined statistical analysis, of reported studies that evaluated cancer risk in patients with Type 2 diabetes. They analyzed seven relevant studies that included more than 32,400 Type 2 diabetic patients who had no other known condition that increased their .

The investigators found that the odds of getting any type of cancer was 0.62 times less—an estimated 38 percent relative risk reduction—with daily continuous use of metformin than for those with no exposure to metformin.

"This risk reduction with metformin use extended to certain types of cancers, specifically colon and breast cancer," Espinoza-Peralta said.

Colorectal cancer and breast cancer are among the cancers that studies have found to occur more often in people with Type 2 diabetes. There was no risk reduction, however, in pancreatic cancer, another type of cancer for which people with Type 2 diabetes are at increased risk, the authors reported.

Metformin, which is the standard recommended initial treatment of Type 2 , may protect against cancer because it regulates activity of an enzyme that suppresses cell growth, according to Espinoza-Peralta.

"There is growing evidence that brings more benefits to diabetic patients beyond glucose control," he said.

Related Stories

Metformin appeared to slow prostate cancer growth

date Apr 01, 2012

The use of metformin in men with prostate cancer before prostatectomy helped to reduce certain metabolic parameters and slow the growth rate of the cancer, according to the results of a phase II study.

Recommended for you

EBV co-infection may boost malaria mortality in childhood

date 14 hours ago

Many people who live in sub-Saharan Africa develop a natural immunity to malaria, through repeated exposure to Plasmodium parasites. Even so, the disease kills close to half a million children per year, according ...

Three important things you didn't know about diabetes

date 20 hours ago

When we think of diabetes, we tend to think of rich people with poor lifestyles. A chronic disease linked with obesity, heart disease and worse outcomes for some infectious diseases, diabetes tends to be ...

Changes observed in HbA1c during ramadan

date May 20, 2015

(HealthDay)—For patients with type 2 diabetes, during Ramadan, the greatest change among metabolic parameters is seen for glycemia, according to a study published online May 13 in the Journal of Diabetes In ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.